Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 1;183:111641.
doi: 10.1016/j.ejmech.2019.111641. Epub 2019 Aug 22.

Recent Advances in the Development of Cyclin-Dependent Kinase 7 Inhibitors

Affiliations
Review

Recent Advances in the Development of Cyclin-Dependent Kinase 7 Inhibitors

Yuou Teng et al. Eur J Med Chem. .

Abstract

Cyclin dependent kinase 7 (CDK7) plays a double role as it activates several other cyclin dependent kinases and participates to the initiation of transcription. This kinase is overexpressed in various types of tumors. Relatively few selective CDK7 inhibitors have been up to now disclosed. Most of these inhibitors belong to two chemical families: pyrazolopyrimidines and pyrazolotriazines on one side and pyrimidines on another side. They also differ by their molecular mechanism of action. Some are acting as competitive inhibitors and some others are covalent inhibitors. With these tools, the understanding of the potential therapeutic interest of CDK7 inhibitors in cancer is rapidly growing. They display antiproliferative activity against various types of tumors and leukemia and synergies have been identified. Two inhibitors are undergoing clinical testing. The most potent compounds inhibit a large number of cell-lines with IC50 < 200 nM.

Keywords: Cancer; Covalent inhibitor; Cyclin-dependent kinase 7; Kinase.

Similar articles

See all similar articles

MeSH terms

LinkOut - more resources

Feedback